Quantitative detection of BCR-ABL fusion transcript in the CML patients

Chronic myeloid leukemia (CML) is one of the most frequent types of leukemia among adult patients. In over 80% of cases, the emergence of this disease is accompanied by the presence of t(9;22) translocation (Philadelphia chromosome) which causes the formation of BCR-ABL (p210) fusion transcript. This fusion transcript is the main hallmark of the disease that is used for monitoring minimal residual disease, and also represents the target for specific therapy (GLEEVEC - imatinib mesylate). In the Laboratory for Molecular Biomedicine we monitor patient response to specific therapy using quantitative monitoring of BCR-ABL fusion transcript by application of Real-time-PCR method, standardized by the Europe Against Cancer group.

It is necessary to deliver 10 ml peripheral blood using 3.8% sodium citrate as anticoagulant in vol/vol ratio 9:1. The sample is required to be delivered fresh, without freezing, during the same day. The samples are accepted every day from 10 to 13h. It is possible to deliver the sample via post express service. The analysis is performed within 10 working days. The results and the bill are sent to the patient's home address, or can be collected personally at the Institute from 10 to 16h every day.

For payment instructions, please contact us.

CONTACT:

• dr Nataša Tošić
• dr Sonja Pavlović

Tel: +381 11 3976 445

Mob: +381 65 3976 445

Fax: +381 11 3975 808

e-mail: zmzg@sezampro.rs